Clinical trials: Diabetic Nephropathy Type 2
Hypertension
Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension
This study is to evaluate the end of treatment effect of Daglutril compared to placebo on top of losartan.
- Trial name
- NCT00160225
- Testing
- Daglutril
- Where
- Italy
- Sponsor
- Solvay Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis
Atrasentan in Patients With Proteinuric Glomerular Diseases
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
- Conditions
- IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
- Trial name
- AFFINITY (NCT04573920)
- Testing
- Atrasentan
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Diabetes Mellitus, Type 2, Diabetic Kidney Disease
Renohemodynamic Effects of Combined empagliflOzin and LosARtan
Worldwide, diabetic kidney disease (DKD) is the most common cause of chronic and end stage kidney disease. In parallel with the ever-increasing rates of obesity and type 2 diabetes (T2D), the incidence of DKD is expected to…
- Trial name
- RECOLAR (NCT04238702)
- Testing
- Empagliflozin 10 MG, Losartan 50Mg Tab
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Amsterdam UMC, location VUmc
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Diabetic Nephropathy Type 2, Type 2 Diabetes
Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status
Chronic inflammation underlies the bidirectional relationship between diabetes and periodontitis, a process that may be further exacerbated in the presence of diabetic nephropathy.
- Conditions
- Diabetic Nephropathy Type 2, Type 2 Diabetes, Periodontitis, Gingivitis
- Trial name
- NCT07498894
- Testing
- clinical periodontal measurements, serum samples, saliva samples
- Where
- Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Pamukkale University
Sleep Apnea, Diabetic Nephropathy Type 2
Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Background: Diabetes, and especially diabetic kidney disease is associated with the development of cardiovascular disease such as calcification in the coronary arteries and heart failure.
- Conditions
- Sleep Apnea, Diabetic Nephropathy Type 2, Coronary Atheroscleroses, Heart Insufficiency
- Trial name
- SLEEP (NCT04549324)
- Where
- Denmark
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Diabetic Kidney Disease
SER150 vs Placebo in Diabetic Kidney Disease
This study is to assess the efficacy and safety of SER150 administered for 24 weeks as a 15 mg twice a day BID dose (except on Day 168 15 mg QD) in participants with type 2 diabetes (T2D) and albuminuria in treatment with either…
- Trial name
- NCT04881123
- Testing
- SER150
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Serodus AS
Diabetic Nephropathy
Evaluating The Roles of Novel Inflammatory Markers Compared to MCP-1 in Type 2 Diabetic Nephropathy
Diabetic kidney disease (DKD) is one of the most common microvascular complications of type 2 diabetes mellitus (T2DM), affecting up to 40% of diabetic patients and accounting for the leading cause of end-stage renal disease…
- Trial name
- NCT07173686
- Volunteers
- 80 people
- Sponsor
- Assiut University
Diabetes Mellitus
Assessment of Serum Magnesium Level with Diabetic Foot Ulceration in Type II Diabetes Associated with Diabetic Nephropathy Patients
Magnesium (Mg), is the fourth most common cation in the body, with an essential role in fundamental biological reactions, whose deficiency provokes biochemical and symptomatic alterations in the human organism.
- Trial name
- NCT06754878
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetes Mellitus Type 2
Patients With Type 2 Diabetes
Diabetes mellitus
- Trial name
- NCT07245082
- Where
- Taiwan
- Volunteers
- 2,000 people
- Sponsor
- National Taiwan University Hospital
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic